In 1935 Domagk1 demonstrated that an azosulfonamide compound (the hydrochloride of 4′-sulfamido-2, 4-diamino-azobenzene) possessed therapeutic activity against streptococcemia in mice. Later experiments showed that a different compound, para-aminobenzenesulfonamide base (sulfanilamide) was equally effective.
During the past two years there have been numerous reports of striking results obtained from the use of sulfanilamide in human beings. Not only have patients with streptococcic infections, such as streptococcic angina, puerperal sepsis and erysipelas, responded well to treatment, but those suffering from epidemic meningitis, pneumonia and gonorrheal urethritis have experienced similar results.
There is a natural tendency to try a new potent remedy in many diseases, in the hope that it may be of benefit. The use of sulfanilamide in pemphigus was suggested by the article by Welsh2 in which he reported isolating a specific streptococcus from the blood of patients with pemphigus.
REPORT OF CASES
S. F., a Jew
CARO MR. PEMPHIGUS: TREATMENT WITH SULFANILAMIDEPRELIMINARY REPORT. Arch Derm Syphilol. 1938;37(2):196–197. doi:10.1001/archderm.1938.01480080029003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: